Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials

Marion Brault, Maxime Annereau, PharmD, Alina Danu, MD, Julien Lazarovici, MD, Claude Chahine, MD, Andrea Varga, Capucine Baldini, Stéphane Champiat, Malik Berhoune, Christophe Massard, François Lemare, Vincent Ribrag, MD, Jean-Marie Michot, MD

Blood (2018) 132 (Supplement 1): 2992.

https://doi.org/10.1182/blood-2018-99-112919

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2018-99-110852

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Tarek Assi, Jean-Marie Michot, MD, Toni Ibrahim, MD MSc, Fabien Le Bras, Karim Belhadj, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Veronique Vergé, Julia Arfi-Rouche, Sophie Cotteret, Christophe Massard, Jean-Charles Soria, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2001.

https://doi.org/10.1182/blood-2018-99-111050

Published: 2018

Journal Articles

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Tony Ibrahim, MD MSc, Tarek Assi, Julien Lazarovici, MD, Maxime Annereau, PharmD, David Ghez, MD PhD, Jean-Marie Michot, MD, Julia Arfi-Rouche, Julien Rossignol, MD PhD, Veronique Vergé, Jacques Bosq, Peggy Dartigues-Cuillères, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4226.

https://doi.org/10.1182/blood-2018-99-117444

Published: 2018

Journal Articles

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Riwa Sakr, MD, Sylvain Pilorge, MD, Stephane De Botton, Claude Chahine, MD, Tereza Coman, MD PhD, Marcel Adler, MD, Jean-Baptiste Micol, MD PhD, Florence Pasquier, MD PhD, Christophe Willekens, MD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Eric Solary, MD, Vincent Ribbag, Jean-Henri Bourhis, Cristina Castilla-LLorente, MD PhD

Blood (2017) 130 (Supplement 1): 5544.

https://doi.org/10.1182/blood.V130.Suppl_1.5544.5544

Published: 2017

Journal Articles

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

Yolla EL Dakdouki, Jean-Marie Michot, MD, Julien Lazarovici, MD, Khalil Saleh, MD, David Ghez, MD PhD, Claude Chahine, MD, Loic Verlingue, Christophe Willekens, MD, Veronique Vergé, Christophe Ferme, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2017) 130 (Supplement 1): 2847.

https://doi.org/10.1182/blood.V130.Suppl_1.2847.2847

Published: 2017

Journal Articles

Strong Expression of the Immune Checkpoint Regulators LAG3 and Tim3 in Hodgkin Lymphoma

Layal el Halabi, Julien Adam, Virginie Marty, Jacques Bosq, MD, Julien Lazarovici, MD, Alina Danu, MD, Vincent Ribrag, MD, David Ghez, PhD MD

Blood (2016) 128 (22): 2952.

https://doi.org/10.1182/blood.V128.22.2952.2952

Published: 2016

Journal Articles

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Khalil Saleh, MD, Christophe Willekens, MD, Jean Edouard Martin, Myriam Kossai, Nadine Khalifé-Saleh, MD, Véronique Saada, PharmD, Nathalie Auger, Alina Danu, MD, Julien Lazarovici, MD, Alexandra Leary, Suzette Delaloge, Jean Henri Bourhis, MD PhD, Éric Solary, MD PhD, Serge Koscielny, Stephane de Botton, Jean-Baptiste Micol, MD PhD

Blood (2016) 128 (22): 4006.

https://doi.org/10.1182/blood.V128.22.4006.4006

Published: 2016

Journal Articles

Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

Khalil Saleh, MD, Jean-Marie Michot, MD, Alina Danu, MD, Julien Lazarovici, MD, Nadine Khalifé-Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Yolla Dakdouki, MD, Jonathan Fahri, Resident, Christophe Willekens, MD, Angela Boros, MD, Julia Arfi-Rouche, MD, Pierre Maroun, MD, Eric Deutsch, PhD MD, Vincent Ribrag, MD, Renaud Mazeron, MD

Blood (2016) 128 (22): 1784.

https://doi.org/10.1182/blood.V128.22.1784.1784

Published: 2016

Journal Articles

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Alina Danu, MD, Sophie Cotteret, PhD, Ludovic Lacroix, Véronique Saada, PharmD, Véronique Vergé, MD, Nathalie Auger, Julien Lazarovici, MD, Edith Carton, Jonathan Farhi, Khalil Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Jean-Marie Michot, MD, Vincent Ribrag, MD

Blood (2016) 128 (22): 5638.

https://doi.org/10.1182/blood.V128.22.5638.5638

Published: 2016

Journal Articles

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

Vincent Ribrag, MD, Khalil Saleh, MD, Alina Danu, MD, Serge Koscielny, Sylvain Pilorge, MD, Cristina castilla-Lorente, MD, David Ghez, Ph DMD, Julien Lazarovici, MD, Jean-Marie Michot, MD, Valerie Lapierre, PhD MD, Kamelia Alexandrova, Julia Arfi-Rouche, MD, Jean-Henri Bourhis, MD PhD

Blood (2016) 128 (22): 4648.

https://doi.org/10.1182/blood.V128.22.4648.4648

Published: 2016

Journal Articles

Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study

Jean-Marie Michot, MD, Theodore Girinsky, MD, Alina Danu, MD, Anna Antosikova, Christophe Ferme, MD, Julien Lazarovici, MD, Christophe Willekens, Ali N Chamseddine, MD, David Ghez, MD PhD, Camille Bigenwald, Jacques Bosq, MD, Stephane de Botton, Renaud Mazeron, MD, Vincent Ribrag, MD

Blood (2014) 124 (21): 1707.

https://doi.org/10.1182/blood.V124.21.1707.1707

Published: 2014

NARROW

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

Strong Expression of the Immune Checkpoint Regulators LAG3 and Tim3 in Hodgkin Lymphoma

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only